Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer
Objectives To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients. Methods We reviewed 78 pathologically proven MIBC patients who underwent MMT including tra...
Gespeichert in:
| Veröffentlicht in: | European radiology 2023-09, Vol.33 (9), p.6245-6255 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6255 |
|---|---|
| container_issue | 9 |
| container_start_page | 6245 |
| container_title | European radiology |
| container_volume | 33 |
| creator | Kimura, Koichiro Yoshida, Soichiro Tsuchiya, Junichi Kitazume, Yoshio Waseda, Yuma Tanaka, Hajime Yokoyama, Minato Toda, Kazuma Yoshimura, Ryoichi Masaya, Ito Koga, Fumitaka Tateishi, Ukihide Fujii, Yasuhisa |
| description | Objectives
To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients.
Methods
We reviewed 78 pathologically proven MIBC patients who underwent MMT including transurethral resection and chemoradiotherapy, followed by partial or radical cystectomy. Treatment response was assessed through histologic evaluation of cystectomy specimens. Two radiologists categorized the index lesions of pretherapeutic MRI according to the 5-point VI-RADS score. The associations of VI-RADS score with the therapeutic effect of MMT were analyzed. The diagnostic performance of VI-RADS scores with a cut-off VI-RADS scores ≤ 2 or ≤ 3 for predicting pathologic complete response to MMT (MMT-CR) was evaluated.
Results
MMT-CR was achieved in 2 (100%) of VI-RADS score 1 (
n
= 2), 16 (84%) of score 2 (
n
= 19), 12 (86%) of score 3 (
n
= 14), 7 (64%) of score 4 (
n
= 11), and 14 (44%) of score 5 (
n
= 32). VI-RADS score was inversely associated with the incidence of MMT-CR (
p
= 0.00049). The cut-off VI-RADS score ≤ 2 and ≤ 3 could predict the favorable therapeutic outcome of MMT with high specificity (0.89 with 95% confidence interval [CI]: 0.71–0.98 and 0.82 with 95% CI: 0.62–0.94, respectively) and high positive predictive value (0.86 with 95% CI: 0.64–0.97 and 0.86 with 95% CI: 0.70–0.95, respectively).
Conclusion
VI-RADS score may serve as an imaging marker in MIBC patients for predicting the therapeutic outcome of MMT.
Clinical relevance statement
Muscle-invasive bladder cancer patients with a lower Vesical Imaging-Reporting and Data System score can be a good candidate for bladder-sparing treatment incorporating multimodal treatment.
Key Points
• Vesical Imaging-Reporting and Data System (VI-RADS) score was potentially valuable for classifying pathologic tumor response in patients with muscle-invasive bladder cancer.
• The likelihood of achieving complete response of multimodal treatment (MMT) decreased with increasing VI-RADS score.
• VI-RADS score could serve as an imaging marker that optimizes patient selection for MMT. |
| doi_str_mv | 10.1007/s00330-023-09627-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2800624267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2848589527</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-bc39ad401f70ee0bf5d8ea4cce5523ff24199b2ed53403d7af24cc19a2eb44f43</originalsourceid><addsrcrecordid>eNp9kcuLFDEQh4Mo7kP_AQ8S8OIlWnn0dPdRdnVdWBR8XUM6XRmypJMxSQ_Mf2_WWR948FRF1Ve_BD5CnnF4xQH61wVASmAgJINxI3o2PCCnXEnBOAzq4V_9CTkr5RYARq76x-RE9qC6cRCnZP2Q9hjoWn3w9UCTo9-weGsCvV7M1sct-4S7lGvrqIkzvTTV0M-HUnGhPtJlDdUvaW58zWjqgrFSl3JbFBuQ-bg3xe-RTsHMM2ZqTbSYn5BHzoSCT-_rOfn67u2Xi_fs5uPV9cWbG2aV4pVNVo5mVsBdD4gwuW4e0ChrseuEdE4oPo6TwLmTCuTcmzaxlo9G4KSUU_KcvDzm7nL6vmKpevHFYggmYlqLFgPARiix6Rv64h_0Nq05tt81Sg3dMHbijhJHyuZUSkand9kvJh80B30nRR-l6CZF_5Sih3b0_D56nRacf5_8stAAeQRKW8Ut5j9v_yf2B-CLmPY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2848589527</pqid></control><display><type>article</type><title>Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kimura, Koichiro ; Yoshida, Soichiro ; Tsuchiya, Junichi ; Kitazume, Yoshio ; Waseda, Yuma ; Tanaka, Hajime ; Yokoyama, Minato ; Toda, Kazuma ; Yoshimura, Ryoichi ; Masaya, Ito ; Koga, Fumitaka ; Tateishi, Ukihide ; Fujii, Yasuhisa</creator><creatorcontrib>Kimura, Koichiro ; Yoshida, Soichiro ; Tsuchiya, Junichi ; Kitazume, Yoshio ; Waseda, Yuma ; Tanaka, Hajime ; Yokoyama, Minato ; Toda, Kazuma ; Yoshimura, Ryoichi ; Masaya, Ito ; Koga, Fumitaka ; Tateishi, Ukihide ; Fujii, Yasuhisa</creatorcontrib><description>Objectives
To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients.
Methods
We reviewed 78 pathologically proven MIBC patients who underwent MMT including transurethral resection and chemoradiotherapy, followed by partial or radical cystectomy. Treatment response was assessed through histologic evaluation of cystectomy specimens. Two radiologists categorized the index lesions of pretherapeutic MRI according to the 5-point VI-RADS score. The associations of VI-RADS score with the therapeutic effect of MMT were analyzed. The diagnostic performance of VI-RADS scores with a cut-off VI-RADS scores ≤ 2 or ≤ 3 for predicting pathologic complete response to MMT (MMT-CR) was evaluated.
Results
MMT-CR was achieved in 2 (100%) of VI-RADS score 1 (
n
= 2), 16 (84%) of score 2 (
n
= 19), 12 (86%) of score 3 (
n
= 14), 7 (64%) of score 4 (
n
= 11), and 14 (44%) of score 5 (
n
= 32). VI-RADS score was inversely associated with the incidence of MMT-CR (
p
= 0.00049). The cut-off VI-RADS score ≤ 2 and ≤ 3 could predict the favorable therapeutic outcome of MMT with high specificity (0.89 with 95% confidence interval [CI]: 0.71–0.98 and 0.82 with 95% CI: 0.62–0.94, respectively) and high positive predictive value (0.86 with 95% CI: 0.64–0.97 and 0.86 with 95% CI: 0.70–0.95, respectively).
Conclusion
VI-RADS score may serve as an imaging marker in MIBC patients for predicting the therapeutic outcome of MMT.
Clinical relevance statement
Muscle-invasive bladder cancer patients with a lower Vesical Imaging-Reporting and Data System score can be a good candidate for bladder-sparing treatment incorporating multimodal treatment.
Key Points
• Vesical Imaging-Reporting and Data System (VI-RADS) score was potentially valuable for classifying pathologic tumor response in patients with muscle-invasive bladder cancer.
• The likelihood of achieving complete response of multimodal treatment (MMT) decreased with increasing VI-RADS score.
• VI-RADS score could serve as an imaging marker that optimizes patient selection for MMT.</description><identifier>ISSN: 1432-1084</identifier><identifier>ISSN: 0938-7994</identifier><identifier>EISSN: 1432-1084</identifier><identifier>DOI: 10.1007/s00330-023-09627-8</identifier><identifier>PMID: 37045982</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Bladder ; Bladder cancer ; Cancer ; Chemoradiotherapy ; Data systems ; Diagnostic Radiology ; Humans ; Imaging ; Internal Medicine ; Interventional Radiology ; Invasiveness ; Magnetic Resonance Imaging - methods ; Medical imaging ; Medicine ; Medicine & Public Health ; Methyl isobutyl carbinol ; Muscles ; Muscles - pathology ; Neuroradiology ; Patients ; Radiology ; Retrospective Studies ; Ultrasound ; Urinary Bladder - pathology ; Urinary Bladder Neoplasms - diagnostic imaging ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - therapy ; Urogenital ; Urological surgery</subject><ispartof>European radiology, 2023-09, Vol.33 (9), p.6245-6255</ispartof><rights>The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to European Society of Radiology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-bc39ad401f70ee0bf5d8ea4cce5523ff24199b2ed53403d7af24cc19a2eb44f43</citedby><cites>FETCH-LOGICAL-c441t-bc39ad401f70ee0bf5d8ea4cce5523ff24199b2ed53403d7af24cc19a2eb44f43</cites><orcidid>0000-0003-2757-8083</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00330-023-09627-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00330-023-09627-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37045982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kimura, Koichiro</creatorcontrib><creatorcontrib>Yoshida, Soichiro</creatorcontrib><creatorcontrib>Tsuchiya, Junichi</creatorcontrib><creatorcontrib>Kitazume, Yoshio</creatorcontrib><creatorcontrib>Waseda, Yuma</creatorcontrib><creatorcontrib>Tanaka, Hajime</creatorcontrib><creatorcontrib>Yokoyama, Minato</creatorcontrib><creatorcontrib>Toda, Kazuma</creatorcontrib><creatorcontrib>Yoshimura, Ryoichi</creatorcontrib><creatorcontrib>Masaya, Ito</creatorcontrib><creatorcontrib>Koga, Fumitaka</creatorcontrib><creatorcontrib>Tateishi, Ukihide</creatorcontrib><creatorcontrib>Fujii, Yasuhisa</creatorcontrib><title>Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><addtitle>Eur Radiol</addtitle><description>Objectives
To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients.
Methods
We reviewed 78 pathologically proven MIBC patients who underwent MMT including transurethral resection and chemoradiotherapy, followed by partial or radical cystectomy. Treatment response was assessed through histologic evaluation of cystectomy specimens. Two radiologists categorized the index lesions of pretherapeutic MRI according to the 5-point VI-RADS score. The associations of VI-RADS score with the therapeutic effect of MMT were analyzed. The diagnostic performance of VI-RADS scores with a cut-off VI-RADS scores ≤ 2 or ≤ 3 for predicting pathologic complete response to MMT (MMT-CR) was evaluated.
Results
MMT-CR was achieved in 2 (100%) of VI-RADS score 1 (
n
= 2), 16 (84%) of score 2 (
n
= 19), 12 (86%) of score 3 (
n
= 14), 7 (64%) of score 4 (
n
= 11), and 14 (44%) of score 5 (
n
= 32). VI-RADS score was inversely associated with the incidence of MMT-CR (
p
= 0.00049). The cut-off VI-RADS score ≤ 2 and ≤ 3 could predict the favorable therapeutic outcome of MMT with high specificity (0.89 with 95% confidence interval [CI]: 0.71–0.98 and 0.82 with 95% CI: 0.62–0.94, respectively) and high positive predictive value (0.86 with 95% CI: 0.64–0.97 and 0.86 with 95% CI: 0.70–0.95, respectively).
Conclusion
VI-RADS score may serve as an imaging marker in MIBC patients for predicting the therapeutic outcome of MMT.
Clinical relevance statement
Muscle-invasive bladder cancer patients with a lower Vesical Imaging-Reporting and Data System score can be a good candidate for bladder-sparing treatment incorporating multimodal treatment.
Key Points
• Vesical Imaging-Reporting and Data System (VI-RADS) score was potentially valuable for classifying pathologic tumor response in patients with muscle-invasive bladder cancer.
• The likelihood of achieving complete response of multimodal treatment (MMT) decreased with increasing VI-RADS score.
• VI-RADS score could serve as an imaging marker that optimizes patient selection for MMT.</description><subject>Bladder</subject><subject>Bladder cancer</subject><subject>Cancer</subject><subject>Chemoradiotherapy</subject><subject>Data systems</subject><subject>Diagnostic Radiology</subject><subject>Humans</subject><subject>Imaging</subject><subject>Internal Medicine</subject><subject>Interventional Radiology</subject><subject>Invasiveness</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methyl isobutyl carbinol</subject><subject>Muscles</subject><subject>Muscles - pathology</subject><subject>Neuroradiology</subject><subject>Patients</subject><subject>Radiology</subject><subject>Retrospective Studies</subject><subject>Ultrasound</subject><subject>Urinary Bladder - pathology</subject><subject>Urinary Bladder Neoplasms - diagnostic imaging</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - therapy</subject><subject>Urogenital</subject><subject>Urological surgery</subject><issn>1432-1084</issn><issn>0938-7994</issn><issn>1432-1084</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kcuLFDEQh4Mo7kP_AQ8S8OIlWnn0dPdRdnVdWBR8XUM6XRmypJMxSQ_Mf2_WWR948FRF1Ve_BD5CnnF4xQH61wVASmAgJINxI3o2PCCnXEnBOAzq4V_9CTkr5RYARq76x-RE9qC6cRCnZP2Q9hjoWn3w9UCTo9-weGsCvV7M1sct-4S7lGvrqIkzvTTV0M-HUnGhPtJlDdUvaW58zWjqgrFSl3JbFBuQ-bg3xe-RTsHMM2ZqTbSYn5BHzoSCT-_rOfn67u2Xi_fs5uPV9cWbG2aV4pVNVo5mVsBdD4gwuW4e0ChrseuEdE4oPo6TwLmTCuTcmzaxlo9G4KSUU_KcvDzm7nL6vmKpevHFYggmYlqLFgPARiix6Rv64h_0Nq05tt81Sg3dMHbijhJHyuZUSkand9kvJh80B30nRR-l6CZF_5Sih3b0_D56nRacf5_8stAAeQRKW8Ut5j9v_yf2B-CLmPY</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Kimura, Koichiro</creator><creator>Yoshida, Soichiro</creator><creator>Tsuchiya, Junichi</creator><creator>Kitazume, Yoshio</creator><creator>Waseda, Yuma</creator><creator>Tanaka, Hajime</creator><creator>Yokoyama, Minato</creator><creator>Toda, Kazuma</creator><creator>Yoshimura, Ryoichi</creator><creator>Masaya, Ito</creator><creator>Koga, Fumitaka</creator><creator>Tateishi, Ukihide</creator><creator>Fujii, Yasuhisa</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2757-8083</orcidid></search><sort><creationdate>20230901</creationdate><title>Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer</title><author>Kimura, Koichiro ; Yoshida, Soichiro ; Tsuchiya, Junichi ; Kitazume, Yoshio ; Waseda, Yuma ; Tanaka, Hajime ; Yokoyama, Minato ; Toda, Kazuma ; Yoshimura, Ryoichi ; Masaya, Ito ; Koga, Fumitaka ; Tateishi, Ukihide ; Fujii, Yasuhisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-bc39ad401f70ee0bf5d8ea4cce5523ff24199b2ed53403d7af24cc19a2eb44f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Bladder</topic><topic>Bladder cancer</topic><topic>Cancer</topic><topic>Chemoradiotherapy</topic><topic>Data systems</topic><topic>Diagnostic Radiology</topic><topic>Humans</topic><topic>Imaging</topic><topic>Internal Medicine</topic><topic>Interventional Radiology</topic><topic>Invasiveness</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methyl isobutyl carbinol</topic><topic>Muscles</topic><topic>Muscles - pathology</topic><topic>Neuroradiology</topic><topic>Patients</topic><topic>Radiology</topic><topic>Retrospective Studies</topic><topic>Ultrasound</topic><topic>Urinary Bladder - pathology</topic><topic>Urinary Bladder Neoplasms - diagnostic imaging</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - therapy</topic><topic>Urogenital</topic><topic>Urological surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kimura, Koichiro</creatorcontrib><creatorcontrib>Yoshida, Soichiro</creatorcontrib><creatorcontrib>Tsuchiya, Junichi</creatorcontrib><creatorcontrib>Kitazume, Yoshio</creatorcontrib><creatorcontrib>Waseda, Yuma</creatorcontrib><creatorcontrib>Tanaka, Hajime</creatorcontrib><creatorcontrib>Yokoyama, Minato</creatorcontrib><creatorcontrib>Toda, Kazuma</creatorcontrib><creatorcontrib>Yoshimura, Ryoichi</creatorcontrib><creatorcontrib>Masaya, Ito</creatorcontrib><creatorcontrib>Koga, Fumitaka</creatorcontrib><creatorcontrib>Tateishi, Ukihide</creatorcontrib><creatorcontrib>Fujii, Yasuhisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kimura, Koichiro</au><au>Yoshida, Soichiro</au><au>Tsuchiya, Junichi</au><au>Kitazume, Yoshio</au><au>Waseda, Yuma</au><au>Tanaka, Hajime</au><au>Yokoyama, Minato</au><au>Toda, Kazuma</au><au>Yoshimura, Ryoichi</au><au>Masaya, Ito</au><au>Koga, Fumitaka</au><au>Tateishi, Ukihide</au><au>Fujii, Yasuhisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer</atitle><jtitle>European radiology</jtitle><stitle>Eur Radiol</stitle><addtitle>Eur Radiol</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>33</volume><issue>9</issue><spage>6245</spage><epage>6255</epage><pages>6245-6255</pages><issn>1432-1084</issn><issn>0938-7994</issn><eissn>1432-1084</eissn><abstract>Objectives
To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients.
Methods
We reviewed 78 pathologically proven MIBC patients who underwent MMT including transurethral resection and chemoradiotherapy, followed by partial or radical cystectomy. Treatment response was assessed through histologic evaluation of cystectomy specimens. Two radiologists categorized the index lesions of pretherapeutic MRI according to the 5-point VI-RADS score. The associations of VI-RADS score with the therapeutic effect of MMT were analyzed. The diagnostic performance of VI-RADS scores with a cut-off VI-RADS scores ≤ 2 or ≤ 3 for predicting pathologic complete response to MMT (MMT-CR) was evaluated.
Results
MMT-CR was achieved in 2 (100%) of VI-RADS score 1 (
n
= 2), 16 (84%) of score 2 (
n
= 19), 12 (86%) of score 3 (
n
= 14), 7 (64%) of score 4 (
n
= 11), and 14 (44%) of score 5 (
n
= 32). VI-RADS score was inversely associated with the incidence of MMT-CR (
p
= 0.00049). The cut-off VI-RADS score ≤ 2 and ≤ 3 could predict the favorable therapeutic outcome of MMT with high specificity (0.89 with 95% confidence interval [CI]: 0.71–0.98 and 0.82 with 95% CI: 0.62–0.94, respectively) and high positive predictive value (0.86 with 95% CI: 0.64–0.97 and 0.86 with 95% CI: 0.70–0.95, respectively).
Conclusion
VI-RADS score may serve as an imaging marker in MIBC patients for predicting the therapeutic outcome of MMT.
Clinical relevance statement
Muscle-invasive bladder cancer patients with a lower Vesical Imaging-Reporting and Data System score can be a good candidate for bladder-sparing treatment incorporating multimodal treatment.
Key Points
• Vesical Imaging-Reporting and Data System (VI-RADS) score was potentially valuable for classifying pathologic tumor response in patients with muscle-invasive bladder cancer.
• The likelihood of achieving complete response of multimodal treatment (MMT) decreased with increasing VI-RADS score.
• VI-RADS score could serve as an imaging marker that optimizes patient selection for MMT.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>37045982</pmid><doi>10.1007/s00330-023-09627-8</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2757-8083</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1432-1084 |
| ispartof | European radiology, 2023-09, Vol.33 (9), p.6245-6255 |
| issn | 1432-1084 0938-7994 1432-1084 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2800624267 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Bladder Bladder cancer Cancer Chemoradiotherapy Data systems Diagnostic Radiology Humans Imaging Internal Medicine Interventional Radiology Invasiveness Magnetic Resonance Imaging - methods Medical imaging Medicine Medicine & Public Health Methyl isobutyl carbinol Muscles Muscles - pathology Neuroradiology Patients Radiology Retrospective Studies Ultrasound Urinary Bladder - pathology Urinary Bladder Neoplasms - diagnostic imaging Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - therapy Urogenital Urological surgery |
| title | Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A23%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20utility%20of%20Vesical%20Imaging-Reporting%20and%20Data%20System%20in%20multimodal%20treatment%20for%20muscle-invasive%20bladder%20cancer&rft.jtitle=European%20radiology&rft.au=Kimura,%20Koichiro&rft.date=2023-09-01&rft.volume=33&rft.issue=9&rft.spage=6245&rft.epage=6255&rft.pages=6245-6255&rft.issn=1432-1084&rft.eissn=1432-1084&rft_id=info:doi/10.1007/s00330-023-09627-8&rft_dat=%3Cproquest_cross%3E2848589527%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2848589527&rft_id=info:pmid/37045982&rfr_iscdi=true |